Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients
Posted innews Oncology Respiratory

Severe Nocturnal Hypoxemia, Not Just Obstructive Sleep Apnea, Predicts Reduced Survival in Non-Small Cell Lung Cancer Patients

The NEOSAS-GFPC study demonstrates that severe sleep-related hypoxemia is an independent predictor of increased mortality in NSCLC patients, highlighting the clinical importance of monitoring nocturnal oxygen saturation beyond traditional apnea indices to improve prognostic accuracy and patient care.
Long-Term Survival Outweighs Short-Term Quality of Life: Why Esophagectomy Remains the Gold Standard for Esophageal Cancer Responders
Posted inGeneral Surgery news Oncology Otorhinolaryngology

Long-Term Survival Outweighs Short-Term Quality of Life: Why Esophagectomy Remains the Gold Standard for Esophageal Cancer Responders

A decision analytical model reveals that while active surveillance offers short-term quality-of-life benefits, standard esophagectomy provides superior 5-year survival and quality-adjusted life-years (QALYs) for esophageal cancer patients achieving clinical complete response after neoadjuvant therapy.
Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma
Posted inGastroenterology news Oncology

Balancing the Scales: The FYN/LCK Kinase Switch Rescues Progenitor T Cells to Overcome Immunotherapy Resistance in Hepatocellular Carcinoma

A breakthrough study reveals that the balance between FYN and LCK kinases acts as a metabolic switch in hepatocellular carcinoma. By modulating this axis through low-dose LCK inhibition, researchers successfully preserved T-cell stemness and mitochondrial health, significantly enhancing the efficacy of immune checkpoint blockade.
Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis
Posted inCardiology news Oncology

Targeting CXCR6: A New Therapeutic Frontier in Immune Checkpoint Inhibitor-Induced Myocarditis

This study identifies CXCR6+ T cells as the primary drivers of immune checkpoint inhibitor-induced myocarditis, especially with anti-LAG-3/PD-1 combinations. Researchers demonstrate that targeting the CXCR6-CXCL16 axis can reduce cardiac inflammation and mortality, offering a promising strategy for managing this life-threatening complication.